Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

• Главные авторы: Jin-Woo Park (Автор), Jong-Min Kim (Автор), Ji Hyeon Noh (Автор), Kyoung-Ah Kim (Автор), Hyewon Chung (Автор), EunJi Kim (Автор), Minja Kang (Автор), Ji-Young Park (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2022-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Dapagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...